1
|
Zheng C, Luo Y, Chen Y, Chen D, Shao C, Huang D, Zhu J, Mao X, Li L, Sun Z. Oral exposure of sulpiride promotes the proliferation of Brown-Norway rat prostates. Exp Ther Med 2020; 19:2551-2562. [PMID: 32256734 PMCID: PMC7086227 DOI: 10.3892/etm.2020.8521] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 02/22/2018] [Indexed: 11/06/2022] Open
Abstract
The aim of the present study was to establish an animal model of prostatic hyperplasia to explore the mechanisms of this disease. Sulpiride, a specific type 2 dopamine receptor antagonist, causes prostate toxicity by stimulating prolactin (PRL) production. Male Brown-Norway (BN) rats were treated intragastrically (i.g.) with sulpiride (40 and 120 mg/kg daily) and vehicle (i.g., daily) for 4 weeks. The results demonstrated that sulpiride-treatment resulted in increased prostate size, prostate lobe weight, epithelial height and acinar luminal area. Furthermore, prostate lobe weight, epithelial height and acinar luminal area of lateral lobes (LP) significantly increased. These effects were dose dependent. Sulpiride treatment increased serum PRL, follicle-stimulating hormone and testosterone levels, while serum luteinizing hormone levels were reduced. Immunohistochemical analysis revealed that proliferating cell nuclear antigen and B-cell lymphoma-2 were significantly increased in certain sulpiride treated groups. Furthermore, estrogen receptor (ER)-α and androgen receptors were upregulated, while ERβ was downregulated in LP. The expression of stromal cell biomarkers, including vimentin, fibronectin and α-smooth muscle actin were significantly increased in LP following 40 mg/kg sulpiride administration. These results suggest that sulpiride causes LP hyperplasia in BN rats by promoting proliferation and inhibiting prostate cell apoptosis via ERα and AR signaling.
Collapse
Affiliation(s)
- Chengcheng Zheng
- School of Pharmacy, Fudan University, Shanghai 200433, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Yongwei Luo
- School of Pharmacy, Fudan University, Shanghai 200433, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Ying Chen
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Dingshi Chen
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Congcong Shao
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Dongyan Huang
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Jing Zhu
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Xiaoyan Mao
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Lei Li
- National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Population and Family Planning Key Laboratory of Contraceptive Drugs and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| | - Zuyue Sun
- School of Pharmacy, Fudan University, Shanghai 200433, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China.,National Evaluation Centre for The Toxicology of Fertility Regulating Drugs, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, P.R. China
| |
Collapse
|
2
|
Görne RC, Wegener T, Kelber O, Feistel B, Reichling J. Randomized double-blind controlled clinical trials with herbal preparations of Serenoa repens fruits in treatment of lower urinary tract symptoms : An overview. Wien Med Wochenschr 2016; 167:177-182. [PMID: 27900565 DOI: 10.1007/s10354-016-0526-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 10/14/2016] [Indexed: 11/25/2022]
Abstract
In this review, results of randomized double-blind controlled clinical trials (RCTs) with extracts of Serenoa repens fruits at a dose of 320 mg/d for the treatment of lower urinary tract symptoms (LUTS) are assessed. Of the RTCs conducted for up to 6 months, a benefit was seen in three of three RTCs with ethanolic, in eight of nine RTCs with hexane, and in one of two RTCs with CO2 extracts. Of the RTCs conducted for more than 6 months, a benefit was seen in two RTCs with hexane and in one RTC with CO2 extracts, whereas one RTC with an ethanolic, two RTCs with hexane, and one RTC with CO2 extracts did not show positive results. As LUTS are dynamic conditions with strong spontaneous fluctuation over time, the majority of patients might expect improvement of single symptoms and thus of quality of life, particularly as the extracts are well tolerated even in long-term treatment.
Collapse
Affiliation(s)
- Rainer C Görne
- Working group "Efficacy and Safety" of the Kooperation Phytopharmaka GbR, Plittersdorfer Str. 218, 53173, Bonn-Bad Godesberg, Germany.
- Praxis für Diabetologie und Naturwissenschaftliche Medizin, Karl-Helfferich-Str. 9A, 67433, Neustadt an der Weinstraße, Germany.
- Sachverständigenbüro für Klinische Pharmakologie und Toxikologie, Kurpfalzstr. 68, 67435, Neustadt an der Weinstraße, Germany.
| | - Tankred Wegener
- Working group "Efficacy and Safety" of the Kooperation Phytopharmaka GbR, Plittersdorfer Str. 218, 53173, Bonn-Bad Godesberg, Germany
- Consulting Herbal Medicinal Products, Brückstr.11, 69469, Weinheim, Germany
| | - Olaf Kelber
- Working group "Efficacy and Safety" of the Kooperation Phytopharmaka GbR, Plittersdorfer Str. 218, 53173, Bonn-Bad Godesberg, Germany
- Scientific Department, Steigerwald Arzneimittelwerk GmbH, Havelstr. 5, 64295, Darmstadt, Germany
| | - Björn Feistel
- Working group "Efficacy and Safety" of the Kooperation Phytopharmaka GbR, Plittersdorfer Str. 218, 53173, Bonn-Bad Godesberg, Germany
- Finzelberg GmbH & Co KG, Koblenzer Str. 48-56, 56626, Andernach, Germany
| | - Jürgen Reichling
- Working group "Efficacy and Safety" of the Kooperation Phytopharmaka GbR, Plittersdorfer Str. 218, 53173, Bonn-Bad Godesberg, Germany
- Institut für Pharmazie und Molekulare Biotechnologie, Universität Heidelberg, Im Neuenheimer Feld 364, 69120, Heidelberg, Germany
| |
Collapse
|